News & Updates
Filter by Specialty:
Mepolizumab benefits held up over time
Beyond 1 year, the humanized monoclonal antibody mepolizumab maintained real-world efficacy and safety in patients with severe eosinophilic asthma in the REALITI-A cohort study, reports an expert at ERS 2021.
Mepolizumab benefits held up over time
25 Sep 2021
Adding cyclophosphamide to glucocorticoids confers no survival benefit in IPF
Adding cyclophosphamide to glucocorticoid treatment in patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) was associated with a numerically increased risk of mortality, according to results of the phase III EXAFIP trial.
Adding cyclophosphamide to glucocorticoids confers no survival benefit in IPF
24 Sep 2021
The air we breathe in the workplace: Is it safe?
What used to be a place that holds a perception of relative safety and minimal health risk to its occupants, the office now appears to be a place that is inching its way towards the other side of the respiratory health spectrum, with office-related occupational asthma on the rise, according to findings from a UK cross-sectional study presented at ERS 2021.
The air we breathe in the workplace: Is it safe?
24 Sep 2021
MV130 immunotherapy prevents COPD exacerbations
Treatment with MV130, a sublingual bacterial immunotherapy, reduces the number of exacerbations in patients with chronic obstructive pulmonary disease (COPD), according to a recent study presented at ERS 2021.
MV130 immunotherapy prevents COPD exacerbations
24 Sep 2021
Doxycycline not recommended for COVID-19 outpatient treatment in older adults
Daily treatment with doxycycline did not shorten recovery time or reduce hospitalization or death in community-dwelling older adults with COVID-19, according to a study from the PRINCIPLE Collaborative Group.
